Eutilex said Thursday that it has completed registering a patent for antibody therapy, “103,” in China.

The patent for “103” was registered as "Anti-Human VSIG4 Antibody and Uses Thereof." Eutilex, which has completed patient registration in the U.S. and Russia, expects to expand its business territory further with its Chinese patent registration.

According to Eutilex, 103, a bifunctional antibody therapy that simultaneously targets macrophages and killer T cells blocks immunosuppressive macrophages (M2) from suppressing T cells in the tumor microenvironment (TME). It converts immunosuppressive macrophages (M2) into immune-activating macrophages (M1). This process activates surrounding immune cells (T cells, NK cells, etc.), increasing the antitumor effect.

Eutilex has actively researched to expand the indications of 103, starting a phase 1 clinical trial of 103 in July last year and presenting the results of a non-clinical study on ovarian cancer at the U.S. SITC (Society for Immunotherapy of Cancer last November.

"Securing patent rights is just as important as R&D and clinical trials for each pipeline," CEO Yoo Yeon-ho said. “We are focusing on our patent strategy by actively securing exclusive and exclusive rights in major countries."